Naftifine


Concise Prescribing Info
Indications/Uses
Skin fungal infections.
Dosage/Direction for Use
Adult : Topical As 1% cream: Apply once daily. As 1% gel: Apply twice daily. Duration: 2-6 wk, depending on the site of infection.
Dosage Details
Topical/Cutaneous
Skin fungal infections
Adult: As hydrochloride: Apply sufficient amount of 1% cream once daily or 1% gel bid, morning and evening. Treatment duration: Tinea cruris and tinea corporis: 2-4 wk; tinea pedis: 4-6 wk; severe infections: May require prolonged treatment.
Contraindications
Hypersensitivity.
Special Precautions
Avoid contact with eyes, nose, mouth and other mucous membranes. Avoid use of occlusive dressings or wrappings. Discontinue use if irritation occurs. Pregnancy and lactation.
Adverse Reactions
Burning, stinging, dryness, redness, pruritus, local irritation, rash, skin tenderness.
Action
Description: Naftifine is a synthetic allylamine antifungal that selectively inhibits the enzyme squalene monooxygenase resulting in reduced synthesis of the primary sterol, ergosterol, within the fungal membrane. It appears to have both fungicidal and fungistatic activity.
Pharmacokinetics:
Absorption: Approx 3-6 % absorbed systemically after application of cream or gel; sufficient concentrations retained in the upper skin layers to inhibit the growth of dermatophytes at this site for 24 hr.
Distribution: Distributed into the milk of rats (topical).
Metabolism: Metabolised to at least 3 metabolites via oxidation of the phenyl and naphthyl rings and by N-dealkylation.
Excretion: Via urine and faeces (as unchanged drug and/or metabolites). Half-life: Approx 2-3 days (topical).
Storage
Cream: Store below 30°C (86°F). Gel: Store at room temperature.
Disclaimer: This information is independently developed by MIMS based on Naftifine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in